Home > Documents in Process > Protein misfolding: understanding biology to classify and treat synucleinopathies. > print

001     282333
005     20251120155102.0
024 7 _ |a 10.1007/s00702-025-02889-0
|2 doi
024 7 _ |a pmid:39932548
|2 pmid
024 7 _ |a 0375-9245
|2 ISSN
024 7 _ |a 0022-3026
|2 ISSN
024 7 _ |a 0300-9564
|2 ISSN
024 7 _ |a 1435-1463
|2 ISSN
037 _ _ |a DZNE-2025-01294
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Outeiro, Tiago Fleming
|0 P:(DE-2719)2814138
|b 0
|e First author
245 _ _ |a Protein misfolding: understanding biology to classify and treat synucleinopathies.
260 _ _ |a Wien [u.a.]
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763650157_2192
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Protein misfolding and aggregation is a major pathological hallmark in a variety of human conditions, including cancer, diabetes, and neurodegeneration. However, we still do not fully understand the role of protein accumulation in disease. Interestingly, recent breakthroughs in artificial intelligence (AI) are having a tremendous impact on our ability to predict three-dimensional protein structures and understand the molecular rules governing protein folding/misfolding. This progress will enable us to understand how intrinsic and extrinsic factors trigger protein misfolding, thereby changing protein function. These changes, in some cases, are related to normal biological responses and, in other cases, associated with pathological alterations, such as those found in many neurodegenerative disorders. Here, we provide a brief historical perspective of how findings in the field of prion diseases and prion biology have enabled tremendous advances that are now forming the basis for our understanding of disease processes and discuss how this knowledge is now emerging as central for our ability to classify, diagnose, and treat devastating neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alpha-synuclein
|2 Other
650 _ 7 |a Biomarkers
|2 Other
650 _ 7 |a Disease classification
|2 Other
650 _ 7 |a Neurodegeneration
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Protein aggregation
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Synucleinopathies: metabolism
|2 MeSH
650 _ 2 |a Synucleinopathies: classification
|2 MeSH
650 _ 2 |a Synucleinopathies: therapy
|2 MeSH
650 _ 2 |a Protein Folding
|2 MeSH
650 _ 2 |a Proteostasis Deficiencies: metabolism
|2 MeSH
650 _ 2 |a Proteostasis Deficiencies: therapy
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 1
|u dzne
700 1 _ |a Lang, Anthony E
|b 2
700 1 _ |a Vieira, Tuane C R G
|b 3
773 _ _ |a 10.1007/s00702-025-02889-0
|g Vol. 132, no. 11, p. 1645 - 1654
|0 PERI:(DE-600)1481655-6
|n 11
|p 1645 - 1654
|t Journal of neural transmission
|v 132
|y 2025
|x 0375-9245
856 4 _ |u https://pub.dzne.de/record/282333/files/DZNE-2025-01292.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/282333/files/DZNE-2025-01292.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2814138
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURAL TRANSM : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21